Skip to main content
Clinical Trials/NCT03968861
NCT03968861CompletedNot Applicable

Neurological Outcome After 24 Months of Age Following Treatment With Xenon Combined With Moderate Hypothermia After Perinatal Asphyxia

Guy's and St Thomas' NHS Foundation Trust3 sites in 1 country69 target enrollmentStarted: August 2014Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
69
Locations
3
Primary Endpoint
Scores on Bayley scales of infant and toddler development

Study Overview

Brief Summary

The objective of this study is to document the outcome at 2-3 years of age of participants of the TOBY Xe trial, to provide preliminary information about the later clinical effects of treatment with Xenon gas combined with moderate hypothermia following perinatal asphyxia. The TOBY Xe trial was a randomised controlled trial of inhaled xenon gas combined with hypothermia for the treatment of perinatal asphyxia. The trial primary outcome was changes on magnetic resonance parameters examined prior to discharge from hospital.

Continuing clinical follow-up of trial participants is important following any therapeutic trial and is essential in early phase trials where information on the clinical effects of the intervention are lacking. Therefore, we have set up this study to determine the major clinical and neurological outcomes of participants of the TOBY Xe trial and to determine whether the magnetic resonance parameters in that trial are qualified to predict outcome following neural rescue therapy. This information is necessary for planning further studies of this intervention.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
2 Years to 3 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Surviving participants in the TOBY Xenon study

Exclusion Criteria

  • Lack of consent to participate

Arms & Interventions

30% Xenon for 24 hours combined with moderate hypothermia

Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial

Intervention: Xenon (Drug)

Outcomes

Primary Outcomes

Scores on Bayley scales of infant and toddler development

Time Frame: at 2-3 years of age

Composite scores of the Cognitive, Language and Motor scales scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160

Relation between magnetic resonance markers and neurodevelopmental outcome

Time Frame: at 2-3 years of age

Peak area Lactate/N Acetyl Aspartate ratio on magnetic resonance spectroscopy and fractional anisotropy on diffusion tensor magnetic resonance imaging

Secondary Outcomes

  • Grade of disability(At 2-3 years of age)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials

Outcome After 24 Months of Participants in... | Clinical Trial